Skip to main content

Advertisement

SpringerLink
Log in

Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I

  • CUTTING EDGE IN AUTOIMMUNITY
  • Published:
Immunologic Research Aims and scope Submit manuscript

An Erratum to this article was published on 06 December 2014

Abstract

The pathogenicity of antibodies against β2-glycoprotein I (anti-β2GPI) depends on multiple factors such as subclass type, epitope binding and avidity. Due to their large heterogeneity, their impact on antiphospholipid syndrome (APS) onset is still not fully clarified. We studied the binding characteristics of IgG anti-β2GPI with known avidity from sera of 201 autoimmune patients (87 with APS, 67 with APS associated with systemic lupus erythematosus (SLE), 47 with only SLE) to six β2GPI peptides corresponding to amino acid clusters on domains I–II, II, III and III–IV by indirect ELISA and evaluated their association with clinical features of APS. Peptides A (LKTPRV; domain I–II), B (KDKATF; domain IV) and C (TLRVYK; domain III) were derived from a hexapeptide phage display library previously shown to react with pathogenic monoclonal anti-β2GPI. Peptides D (NGPANSK; domain III), E (YNPLWFV; domain II) and F (KMDGNHP; domain III–IV) represent surface amino acid clusters on β2GPI. The percentage of patients positive for peptides were observed as follows: 30.3 % for peptide D, 28.90 % for B, 25.9 % for C, 24.9 % for E, 24.4 % for F and 10.0 % for A. The anti-peptide antibodies in studied serum samples were predominantly of heterogeneous avidity, followed by law avidity anti-peptide antibodies, whereas only a few were of high avidity. Positive and negative correlations were found between several anti-peptide antibodies and the rate of thrombosis. Our results indicated diverse reactivity of IgG anti-β2GPI to different epitopes on β2GPI. Classification of IgG anti-β2GPI into subgroups regarding epitope specificity and avidity could represent an additional tool in understanding their pathogenicity in APS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. doi:10.1111/j.1538-7836.2006.01753.x.

    Article  CAS  PubMed  Google Scholar 

  2. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–11. doi:10.1002/1529-0131(199907)42:7<1309:AID-ANR1>3.0.CO;2-F.

    Article  CAS  PubMed  Google Scholar 

  3. Cervera R, Asherson RA. Antiphospholipid syndrome. In: Shoenfeld Y, Cervera R, Gershwin ME, editors. Diagnostic criteria in autoimmune diseases. Totowa: Humana Press; 2008. p. 9–14.

    Chapter  Google Scholar 

  4. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27. doi:10.1002/art.10187.

    Article  PubMed  Google Scholar 

  5. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.

    Article  CAS  PubMed  Google Scholar 

  6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.

    Article  CAS  PubMed  Google Scholar 

  7. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330–9. doi:10.1038/nrrheum.2011.52.

    Article  CAS  PubMed  Google Scholar 

  8. de Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol. 2008;4(4):192–9. doi:10.1038/ncprheum0740.

    Article  PubMed  Google Scholar 

  9. Espinosa G, Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol. 2010;6(5):296–300. doi:10.1038/nrrheum.2010.47.

    Article  CAS  PubMed  Google Scholar 

  10. Artenjak A, Lakota K, Frank M, Cucnik S, Rozman B, Bozic B, et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev. 2012;11(12):873–82. doi:10.1016/j.autrev.2012.03.002.

    Article  CAS  PubMed  Google Scholar 

  11. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112(21):3337–47. doi:10.1161/CIRCULATIONAHA.104.507996.

    Article  PubMed  Google Scholar 

  12. Lin F, Murphy R, White B, Kelly J, Feighery C, Doyle R, et al. Circulating levels of beta2-glycoprotein I in thrombotic disorders and in inflammation. Lupus. 2006;15(2):87–93.

    Article  CAS  PubMed  Google Scholar 

  13. Horstman LL, Jy W, Bidot CJ, Ahn YS, Kelley RE, Zivadinov R, et al. Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation. 2009;6:3. doi:10.1186/1742-2094-6-3.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci USA. 1984;81(12):3640–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA. 1993;90(6):2141–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 1999;18(22):6228–39. doi:10.1093/emboj/18.22.6228.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Sodin-Semrl S, Frank M, Ambrožič A, Pavlič J, Šuštar V, Čučnik S, et al. Interactions of phospholipid binding proteins with negatively charged membranes: β2-glycoprotein I as a model mechanism. In: Leitmannova Liu A, editor. Advances in planar lipid bilayers and liposomes, 1st ed. Amsterdam: Elsevier; 2008. p. 243–73.

    Chapter  Google Scholar 

  18. Agar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, Urbanus RT, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116(8):1336–43. doi:10.1182/blood-2009-12-260976.

    Article  CAS  PubMed  Google Scholar 

  19. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006;107(5):1916–24. doi:10.1182/blood-2005-05-1943.

    Article  PubMed  Google Scholar 

  20. Wang MX, Kandiah DA, Ichikawa K, Khamashta M, Hughes G, Koike T, et al. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol. 1995;155(3):1629–36.

    CAS  PubMed  Google Scholar 

  21. Kasahara H, Matsuura E, Kaihara K, Yamamoto D, Kobayashi K, Inagaki J, et al. Antigenic structures recognized by anti-beta2-glycoprotein I auto-antibodies. Int Immunol. 2005;17(12):1533–42. doi:10.1093/intimm/dxh330.

    Article  CAS  PubMed  Google Scholar 

  22. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev. 2012;12(2):313–7. doi:10.1016/j.autrev.2012.05.006.

    Article  CAS  PubMed  Google Scholar 

  23. Ambrozic A, Avicin T, Ichikawa K, Kveder T, Matsuura E, Hojnik M, et al. Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis. Int Immunol. 2002;14(7):823–30.

    Article  CAS  PubMed  Google Scholar 

  24. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis. 2004;63(11):1478–82. doi:10.1136/ard.2003.017939.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. de Laat B, Derksen RH, de Groot PG. High-avidity anti-beta2 glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta2 glycoprotein I antibodies. J Thromb Haemost. 2006;4(7):1619–21. doi:10.1111/j.1538-7836.2006.02002.x.

    Article  PubMed  Google Scholar 

  26. Zager U, Irman S, Lunder M, Skarabot M, Musevic I, Hodnik V, et al. Immunochemical properties and pathological relevance of anti-beta2-glycoprotein I antibodies of different avidity. Int Immunol. 2011;23(8):511–8. doi:10.1093/intimm/dxr043.

    Article  CAS  PubMed  Google Scholar 

  27. Zager U, Lunder M, Čučnik S, Kveder T, Rozman B, Božič B. Immunodominant epitopes of beta2-glycoprotein I for high avidity antibodies. In: 8th International congress on autoimmunity. Granada, Spain: Geneva: Kenes International; 2012.

  28. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA. 1999;96(9):5164–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Cucnik S, Kveder T, Artenjak A, Ulcova Gallova Z, Swadzba J, Musial J, et al. Avidity of anti-beta2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Lupus. 2012;21(7):764–5. doi:10.1177/0961203312440057.

    Article  CAS  PubMed  Google Scholar 

  30. Iverson GM, von Muhlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun. 2006;27(4):266–71. doi:10.1016/j.jaut.2006.09.007.

    Article  CAS  PubMed  Google Scholar 

  31. Shoenfeld Y, Krause I, Kvapil F, Sulkes J, Lev S, von Landenberg P, et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol. 2003;23(5):377–83.

    Article  CAS  PubMed  Google Scholar 

  32. Cucnik S, Bozic B, Kveder T, Tomsic M, Rozman B. Avidity of anti-beta2-glycoprotein I and thrombosis or pregnancy loss in patients with antiphospholipid syndrome. Ann N Y Acad Sci. 2005;1051:141–7. doi:10.1196/annals.1361.055.

    Article  CAS  PubMed  Google Scholar 

  33. Cucnik S, Kveder T, Ulcova-Gallova Z, Swadzba J, Musial J, Valesini G, et al. The avidity of anti-beta2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus. 2011;20(11):1166–71. doi:10.1177/0961203311406308.

    Article  CAS  PubMed  Google Scholar 

  34. Artenjak A, Kozelj M, Lakota K, Cucnik S, Bozic B, Sodin-Semrl S. High avidity anti-b2-glycoprotein I antibodies activate human coronary artery endothelial cells and trigger peripheral blood mononuclear cell migration. Eur J Inflamm. 2013;11(2):385–96.

    CAS  Google Scholar 

  35. Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med. 2011;49(3):447–61. doi:10.1515/CCLM.2011.064.

    Article  CAS  PubMed  Google Scholar 

  36. Cucnik S, Ambrozic A, Bozic B, Skitek M, Kveder T. Anti-beta2-glycoprotein I ELISA: methodology, determination of cut-off values in 434 healthy Caucasians and evaluation of monoclonal antibodies as possible international standards. Clin Chem Lab Med. 2000;38(8):777–83. doi:10.1515/CCLM.2000.111.

    Article  CAS  PubMed  Google Scholar 

  37. Avcin T, Ambrozic A, Bozic B, Accetto M, Kveder T, Rozman B. Estimation of anticardiolipin antibodies, anti-beta2 glycoprotein I antibodies and lupus anticoagulant in a prospective longitudinal study of children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20(1):101–8.

    CAS  PubMed  Google Scholar 

  38. Banzato A, Pozzi N, Frasson R, De Filippis V, Ruffatti A, Bison E, et al. Antibodies to domain I of beta(2)glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res. 2011;128(6):583–6. doi:10.1016/j.thromres.2011.04.021.

    Article  CAS  PubMed  Google Scholar 

  39. Muller C, Thaler M, Schlichtiger A, Schreiegg A, Balling G, Steigerwald U, et al. beta2-glycoprotein I-derived peptides as antigenic structures for the detection of antiphospholipid antibodies. J Thromb Haemost. 2010;8(9):2073–5. doi:10.1111/j.1538-7836.2010.03987.x.

    Article  CAS  PubMed  Google Scholar 

  40. Metzger J, von Landenberg P, Kehrel M, Buhl A, Lackner KJ, Luppa PB. Biosensor analysis of beta2-glycoprotein I-reactive autoantibodies: evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies. Clin Chem. 2007;53(6):1137–43. doi:10.1373/clinchem.2006.079632.

    Article  CAS  PubMed  Google Scholar 

  41. Pierangeli SS, Blank M, Liu X, Espinola R, Fridkin M, Ostertag MV, et al. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J Autoimmun. 2004;22(3):217–25. doi:10.1016/j.jaut.2004.01.002.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The study is in accordance with the Helsinki Declaration of 1975, revised in 1983 and was approved by the National Ethical Committee (No. 163/02/09). This work was funded by the National Research Program Grant No. P3-0314 from the Ministry of Higher Education, Science and Technology, Slovenia.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Lek Pharmaceuticals d.d., Sandoz Biopharmaceuticals Mengeš, Kolodvorska 27, 1234, Menges, Slovenia

    A. Artenjak

  2. Faculty of Pharmacy, University of Ljubljana, 1000, Ljubljana, Slovenia

    I. Locatelli & B. Božič

  3. Laboratory for Immunology, Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, 1000, Ljubljana, Slovenia

    H. Brelih, D. M. Simonič, A. Ambrožič, S. Sodin-Semrl, B. Božič & S. Čučnik

  4. Department of Gynaecology and Obstetrics, Genetics and Medical School of Charles University, 32600, Plzen-Cernice, Czech Republic

    Z. Ulcova-Gallova

  5. Department of Medicine, Jagiellonian University Medical College, 31-008, Kraków, Poland

    J. Swadzba, J. Musial & T. Iwaniec

  6. Bezhanijska Kosa, University Medical Centre, Belgrade University, 11080, Belgrade, Serbia

    L. Stojanovich

  7. Dipartimento Medicina Interna e Specialità Mediche, Rheumatology, Lupus Clinic, La Sapienza, University of Rome, 00161, Rome, Serbia

    F. Conti & G. Valesini

  8. Department of Allergology, Rheumatology and Clinical Immunology, University Medical Centre, University Children’s Hospital Ljubljana, 1000, Ljubljana, Slovenia

    T. Avčin

  9. Clinical and experimental Immunology, Maastricht University, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands

    J. W. Cohen Tervaert

  10. Sheba Medical Center, The Zabludowicz Center for Autoimmune Diseases, 52621, Tel-Hashomer, Israel

    Y. Shoenfeld & M. Blank

  11. Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, 69978, Ramat Aviv, Israel

    M. Blank

  12. Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska, 6000, Koper, Slovenia

    S. Sodin-Semrl

Authors
  1. A. Artenjak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Locatelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Brelih
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. M. Simonič
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Z. Ulcova-Gallova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Swadzba
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Musial
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Iwaniec
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Stojanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Valesini
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. T. Avčin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J. W. Cohen Tervaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Y. Shoenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M. Blank
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A. Ambrožič
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. S. Sodin-Semrl
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. B. Božič
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. S. Čučnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Čučnik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Artenjak, A., Locatelli, I., Brelih, H. et al. Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I. Immunol Res 61, 35–44 (2015). https://doi.org/10.1007/s12026-014-8578-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-014-8578-0

Keywords

Search

Navigation